Dicot nomination committee appointed for AGM 2020

According to the instruction that was adopted at the Dicot AN (Publ) AGM May 16, 2019, the nomination committee should consist of three members. 

November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nomination Committee, which is to be appointed for the period until a new Nomination Committee has been appointed, will have three members, which will be appointed by the three largest shareholders of the company in terms of votes.

As soon as reasonably possible after the end of the third quarter, the Chairman of the Board should contact the three largest shareholders in terms of votes recorded in the share register maintained by Euroclear Sweden AB and request that within a reasonable time in the circumstances, although not more than 30 days, they state the name of the individual such shareholder wishes to appoint as a member of the Nomination Committee. If one of the three largest shareholders does not wish to exercise its entitlement to appoint a member of the Nomination Committee, the next shareholder in turn will be offered the entitlement to appoint a member of the Nomination Committee.

The committee shall appoint a Chairman of the Nomination Committee within itself. The Chairman of the Board or other Director may never serve as Chairman of the Nomination Committee.

Based on the above, and as of September 30, 2019, the nomination committee for the 2020 AGM has been determined to consist of the following persons: 

  •  Jarl Wikberg
  •  Bengt Walfridsson
  •  Bertil Lindkvist  

The suggestion from the nomination committee will be presented in the notice to the AGM 2020 as well as on the Company website, https://www.dicot.se/ 

Shareholders who wish to leave suggestions to the nomination committee are welcome to contact the nomination committee at the Company address. In order for the nomination committee to take a suggestion into account, the suggestion must have been received in a timely manner before the AGM, January 31, 2020 at the latest. 

For further information, please contact:

Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
E-mail: julie.silber@dicot.se 
www.dicot.se 

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 26, 2019.

About Dicot AB

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to esnrich patients" lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company"s lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.  

Nerladdningsbara filer

Studie med läkemedelskandidaten Libiguin ® har initierats

Pressmeddelande: Uppsala, 4 mars 2020. Dicot AB (publ) meddelar idag att den första studien med läkemedelskandidaten Libiguin® har initierats. Detta genom ett forskningssamarbete med Pelvipharm, en världsledande kontraktsforskningsorganisation (CRO) baserad i Frankrike.


Dicot AB bokslutskommuniké 2019

Pressmeddelande: Uppsala, 27 februari 2020. Dicot ABs (publ) bokslutskommuniké för 2019 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Korrigerad version: Dicot utökar ledningsteamet

(Tidigare idag, den 11 december 2019, publicerades ett pressmeddelande felaktigt med hänvisning till marknadsmissbruksförordningen (MAR). Informationen i pressmeddelandet är regulatorisk men inte av MAR-karaktär).

Jessica Roxhed tillträder som ny CFO på Dicot, Julie Silbers roll som Director of Investor Relations utökas och Gabriela Urquilla blir ansvarig för externkommunikation från och med den 15 december 2019.


Correction: Dicot Expands its Management Team

(Earlier today, December 11, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature).

Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.


Dicot utökar ledningsteamet

Jessica Roxhed tillträder som ny CFO på Dicot, Julie Silbers roll som Director of Investor Relations utökas och Gabriela Urquilla blir ansvarig för externkommunikation från och med den 15 december 2019.


Dicot Expands its Management Team

Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.


Dicot AB redovisar delårsresultat för tredje kvartalet 2019

Delårsresultat juli-sept 2019

  • Nettoomsättningen uppgick till 75 (0) KSEK
  • Resultat före skatt uppgick till

-3 183 (-1 375) KSEK

  • Resultat per aktie uppgick till -0,41 (-0,27) SEK

Rapportperiod januari - sept 2019

  • Nettoomsättningen uppgick till 75 (0) MSEK
  • Resultat före skatt uppgick till -9 866 (-4 366) KSEK

Resultat per aktie uppgick till -1,27 (-0,33) SEK


Korrigerad version: Valberedning utsedd inför årsstämma 2020 i Dicot AB (publ)

(Det föregående pressmeddelandet skickades ut klockan 08:00 CET och har uppdaterats för att korrigera ett stavfel. Ingenting annat skiljer sig från det föregående pressmeddelandet.)

November 26, 2019, Uppsala, Sverige - Dicot AB (publ) ("Dicot" eller "företaget") Valberedningen, som ska utses för perioden tills en ny valberedning har utsetts, kommer att ha tre ledamöter, som utses av de tre största aktieägarna i bolaget i röster.


Correction: Dicot nomination committee appointed for AGM 2020

(The previous press release was sent out at 08:00 CET and has been updated to correct a spelling error. Nothing else differs from the previous press release.)

November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nomination Committee, which is to be appointed for the period until a new Nomination Committee has been appointed, will have three members, which will be appointed by the three largest shareholders of the company in terms of votes.


Valberedning utsedd inför årsstämma 2020 i Dicot AB (publ)

November 26, 2019, Uppsala, Sverige - Dicot AB (publ) ("Dicot" eller "företaget") Valberedningen, som ska utses för perioden tills en ny valberedning har utsetts, kommer att ha tre ledamöter, som utses av de tre största aktieägarna i bolaget i röster.


Dicot nomination committee appointed for AGM 2020

According to the instruction that was adopted at the Dicot AN (Publ) AGM May 16, 2019, the nomination committee should consist of three members. 

November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nomination Committee, which is to be appointed for the period until a new Nomination Committee has been appointed, will have three members, which will be appointed by the three largest shareholders of the company in terms of votes.


Dicot tecknar avtal om kontraktsforskning med Pelvipharm

6 november 2019, Uppsala - Dicot AB (publ) ("Dicot" eller "Bolaget" meddelar i dag att bolaget har ingått ett forskningssamarbete med Pelvipharm, en världsledande kontraktsforskningsorganisation (CRO) baserad i Frankrike. Syftet med forskningssamarbetet är att identifiera verkningsmekanismen hos Libiguin®, vilket är ett avgörande steg för att fastställa läkemedlets exakta kliniska användningsområde och för att det ska kunna registreras som ett godkänt läkemedel.


Dicot signs Agreement for Contract Research with Pelvipharm

November 6, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") announced today that the company has entered into a research collaboration agreement with Pelvipharm, a world-leading contract research organization (CRO) based in France. This research collaboration is focused on the identification of Libiguin's® mechanisms of action, which is a key step towards defining the exact domain for clinical use of the drug, and to support its registration as an approved drug.


Dicot stärker teamet med ny projektledare för materialinköp

Pressmeddelande: Uppsala, 4 oktober2019. Dicot AB (publ), utvecklare av läkemedel för sexuell dysfunction, meddelade i dag att bolaget har anställt Catarina Malmberg som ny Chef för leverantörskedjan. Hon tillträder den 1 november 2019. I den här rollen kommer Catarina Malmberg att ansvara både för tillgången på råvaror och produktion genom hela leverantörskedjan.


Dicot Strenghten"s Team with new Supply Chain Director

Press release: Uppsala, October 4, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Catarina Malmberg as its Supply Chain Director, effective of November 1, 2019. In this role Malmberg will be responsible for both supply of raw material and production through the entire supply chain.


Pressmeddelande Omvandling av betalda tecknade units (BTU) till aktier och teckningsoptioner av serie 2019/2020

Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört en nyemission om cirka 20,3 MSEK under perioden den 3 september till den 17 september 2019 ("Företrädesemissionen"). I samband med Företrädesemissionen genomförde Bolaget en riktad emission om cirka 2 MSEK ("Övertilldelningsemissionen"). Företrädesemissionen tecknades till 244 procent och Övertilldelningsemissionen blev fulltecknad. Totalt emitterades 7 790 823 units i Företrädesmissionen och 779 082 aktier i Övertilldelningsemissionen, båda till en teckningskurs om 2,60 SEK. Emissionslikviden från Företrädesemissionen uppgick till 20 281 75 SEK och emissionslikviden för Övertilldelningsemissionen uppgick till 2 025 613 SEK.


Conversion of paid subscribed units (BTU) to shares and warrants of series 2019/2020

Dicot AB (publ) ("Dicot" or the "Company") conducted a rights issue of approximately SEK 20.3 million during the period of September 3 - September 17, 2019 (the "Rights Issue"). In connection to the Rights Issue, the Company also conducted a directed issue of approximately SEK 2 million (the "Overallotment Issue"). The Rights Issue was subscribed with 244 percent and the Overallotment Issue was fully subscribed. In total, 7,790,823 units were issued in the Rights Issue and 779,082 shares were issued in the Overallotment Issue, both at a subscription price of SEK 2.60. Net proceeds from the Rights Issue amounted to SEK 20,281,75, and net proceeds from the Overallotment Issue amounted to SEK 2,025,613.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär